Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Protein Networks

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Early neutrophil infiltration promotes TRIMELVax-induced antitumor immunity by linking local inflammation to tumor control.

Oncoimmunology·2026

Same author

Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial.

Nature communications·2026

Same author

Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring.

NPJ breast cancer·2026

Same author

From prediction to precision: Biomarker discovery and predictive modeling for personalized immune checkpoint blockade therapy.

European journal of cancer (Oxford, England : 1990)·2026

Same author

The AICL-KLRF1 axis supports CD4-CD8 T cell communication and cytokine competence in pre-exhausted CD8<sup>+</sup> T cells.

EMBO reports·2026

Same author

Cell-State-Specific Drug Responses are Associated With Differences in Signaling Network Wiring.

Molecular & cellular proteomics : MCP·2026

Same journal

Topological skeleton analysis for network-based shape representation in biology and beyond.

iScience·2026

Same journal

Condition-specific neural signatures of reactivation during post-retrieval rest: An EEG study.

iScience·2026

Same journal

Multi-chaotic signal identification employing a causal cross-correlation neural network.

iScience·2026

Same journal

Repeated insertions at positions 261-280 in KPC-2 highlight a ceftazidime-avibactam resistance hotspot.

iScience·2026

Same journal

ROS inhibits microtubule dynamics and cell growth heterogeneity during Arabidopsis sepal morphogenesis.

iScience·2026

Same journal

Type 1 diabetes alters early macrophage-<i>Mycobacterium tuberculosis</i> transcriptional coordination during infection.

iScience·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Aug 31, 2025

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

Identifying mutant-specific multi-drug combinations using comparative network reconstruction.

Evert Bosdriesz¹, João M Fernandes Neto², Anja Sieber^3,4

¹Bioinformatics, Computer Science, VU Amsterdam, De Boelelaan 1111, Amsterdam 1081 HV, the Netherlands.

|August 22, 2022

Summary

This summary is machine-generated.

Developing new cancer treatments, this study introduces a pipeline to find effective, low-dose multi-drug combinations. The research identified anti-selective combinations, improving drug discovery for targeted cancer therapy.

Keywords:

Bioinformatics In silico biology Pharmacoinformatics Systems biology

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Experiment Videos

Last Updated: Aug 31, 2025

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Area of Science:

Oncology
Pharmacology
Systems Biology

Background:

Targeted cancer therapies inhibiting aberrant signaling pathways are crucial but often face limited response duration.
Multi-drug combinations offer potential to overcome resistance and improve efficacy, but require careful selection to minimize toxicity.
Identifying optimal drug combinations necessitates understanding complex cellular signaling networks and their impact on cell viability.

Purpose of the Study:

To develop and validate a computational pipeline for identifying promising multi-drug combinations for cancer treatment.
To predict the effects of drug combinations on cancer cell viability based on reconstructed signaling networks.
To assess the selectivity and efficacy of drug combinations in PI3K-mutant versus wild-type cancer cells.

Main Methods:

Perturbation of isogenic PI3K mutant and wild-type cell lines with a defined drug set.
Measurement of cellular signaling states and cell viability following drug treatment.
Reconstruction of cellular signaling networks and modeling of signaling response to cell viability.
Prediction and experimental validation of multi-drug combination effects.

Main Results:

The developed models predicted that no tested combination selectively reduced the viability of PI3K mutant cells.
Twenty-five out of thirty predicted anti-selective combinations were experimentally validated.
The pipeline demonstrated efficiency in prioritizing multi-drug combinations from a large search space.

Conclusions:

The computational pipeline enables efficient identification and prioritization of potential multi-drug combinations for cancer therapy.
While no combination showed selective anti-mutant activity, the validation of anti-selective effects highlights the pipeline's predictive power.
This approach aids in navigating the vast landscape of drug combinations to find therapeutically relevant strategies.